Prelude Therapeutics, Eli Lilly, PRT13722, KAT6A degrader, breast cancer, HR+/HER2-negative, abemaciclib, imlunestrant, Inluriyo, CDK4/6 inhibitor, endocrine therapy

WILMINGTON, Del. — October 13, 2026 Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, announced a clinical trial...